AU2016325556B2 - Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate - Google Patents

Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate Download PDF

Info

Publication number
AU2016325556B2
AU2016325556B2 AU2016325556A AU2016325556A AU2016325556B2 AU 2016325556 B2 AU2016325556 B2 AU 2016325556B2 AU 2016325556 A AU2016325556 A AU 2016325556A AU 2016325556 A AU2016325556 A AU 2016325556A AU 2016325556 B2 AU2016325556 B2 AU 2016325556B2
Authority
AU
Australia
Prior art keywords
subject
liver disease
phenylacetate
ornithine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016325556A
Other languages
English (en)
Other versions
AU2016325556A1 (en
Inventor
Cristina R. Bosoi
Chantal BÉMEUR
Marc-André CLÉMENT
Mariana Macedo Oliveira
Christopher F. Rose
Mélanie TREMBLAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of AU2016325556A1 publication Critical patent/AU2016325556A1/en
Application granted granted Critical
Publication of AU2016325556B2 publication Critical patent/AU2016325556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016325556A 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate Active AU2016325556B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US62/233,002 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (2)

Publication Number Publication Date
AU2016325556A1 AU2016325556A1 (en) 2018-03-01
AU2016325556B2 true AU2016325556B2 (en) 2023-02-16

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016325556A Active AU2016325556B2 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Country Status (7)

Country Link
US (1) US20200206174A1 (enExample)
EP (1) EP3352748A4 (enExample)
JP (1) JP6989495B2 (enExample)
AU (1) AU2016325556B2 (enExample)
CA (1) CA2998490A1 (enExample)
HK (1) HK1257679A1 (enExample)
WO (1) WO2017053613A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
CA3100944A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
JP2022533569A (ja) * 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2010115055A1 (en) * 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010144498A2 (en) * 2009-06-08 2010-12-16 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2010115055A1 (en) * 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010144498A2 (en) * 2009-06-08 2010-12-16 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL SIBAE M.R. et al., "Current trends in the treatment of hepatic encephalopathy", Therapeutics and Clinical Risk Management, (2009), vol. 5, pages 617 - 626 *
CIECKO-MICHALSKA I. et al., "Pathogenesis of Hepatic Encephalopathy", Gastroenterology Research and Practice (2012, vol. 2012, no. 642108, (2012), URL: https://www.hindawi.com/journals/grp/2012/642108/cta, (2016-12-08) *
CLÉMENT M.-A. et al, 50th Annual Meeting European Association for the Study of the Liver, Journal of Hepatology, (2015-04), vol. 62, no. Supplement 2, page S295 *
MARC ORIA; JORDI ROMERO-GIMNEZ; JOS ANTONIO ARRANZ; ENCARNACI RIUDOR; NRIA RAGUER; JUAN CRDOBA;: "Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 1, 22 June 2011 (2011-06-22), AMSTERDAM, NL , pages 109 - 114, XP028341033, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2011.06.026 *
MARIA JOVER-COBOS, LORETTE NOIRET, YALDA SHARIFI, RAJIV JALAN: "Ornithine phenylacetate revisited", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC - PLENUM PUBLISHERS, NEW YORK, NY, US, vol. 28, no. 2, 1 June 2013 (2013-06-01), US , pages 327 - 331, XP055324717, ISSN: 0885-7490, DOI: 10.1007/s11011-013-9391-5 *
ROGER F. BUTTERWORTH: "Neuronal cell death in hepatic encephalopathy", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 22, no. 3-4, 13 September 2007 (2007-09-13), Ne , pages 309 - 320, XP019554863, ISSN: 1573-7365, DOI: 10.1007/s11011-007-9072-3 *
ROMERO-GÓMEZ M. ET AL.: "Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure", JOURNAL OF HEPATOLOGY, vol. 62, no. 2, 2015, pages 437 - 447, DOI: doi:10.1016/j.jhep.2014.09.005 *
VENTURA-COTS M. ET AL.: "Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients An Open-label, Dose-escalating, Single-cohort Study", JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 47, no. 10, Nov. 2013, pages 881 - 887 *

Also Published As

Publication number Publication date
EP3352748A4 (en) 2019-06-05
WO2017053613A8 (en) 2017-04-27
AU2016325556A1 (en) 2018-03-01
WO2017053613A1 (en) 2017-03-30
US20200206174A1 (en) 2020-07-02
JP6989495B2 (ja) 2022-01-05
HK1257679A1 (zh) 2019-10-25
CA2998490A1 (en) 2017-03-30
JP2018531929A (ja) 2018-11-01
EP3352748A1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
AU2016325556B2 (en) Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US12503425B2 (en) Methods of treating or controlling cytotoxic cerebral edema
Peng et al. Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke
Rani et al. In vitro and in vivo studies reveal the beneficial effects of chlorogenic acid against ER stress mediated ER-phagy and associated apoptosis in the heart of diabetic rat
Chen et al. Protective effects of Salidroside on cardiac function in mice with myocardial infarction
Zhu et al. Verbascoside protects from LPS-induced septic cardiomyopathy via alleviating cardiac inflammation, oxidative stress and regulating mitochondrial dynamics
Saccà et al. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2
Matsui et al. Dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3β activation
US9949991B2 (en) Methods of treating aquaporin-mediated conditions
AU2016308641A1 (en) Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
Li et al. All-Trans Retinoic Acid Ameliorates the Early Experimental Cerebral Ischemia–Reperfusion Injury in Rats by Inhibiting the Loss of the Blood–Brain Barrier via the JNK/P38MAPK Signaling Pathway
Syvänen et al. Alteration in P-glycoprotein functionality affects intrabrain distribution of quinidine more than brain entry—a study in rats subjected to status epilepticus by kainate
Wang et al. Neuroprotective effect of salvianolate lyophilized injection against cerebral ischemia in type 1 diabetic rats
Zhou et al. Icariin improves oxidative stress injury during ischemic stroke via inhibiting mPTP opening
Liang et al. Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis
Tigani et al. Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging
Cavaglia et al. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs
Migliati et al. Na+–K+–2Cl− cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4
Kagi et al. The NLRP3 inflammasome is a major cause of acute renal failure induced by polypeptide antibiotics
Lin et al. Bradykinin postconditioning protects rat hippocampal neurons after restoration of spontaneous circulation following cardiac arrest via activation of the AMPK/mTOR signaling pathway
Vijikumar et al. Novel mitoNEET ligand NL-1 improves therapeutic outcomes in an aged rat model of cerebral ischemia/reperfusion injury
Liang et al. Glycyrrhetinic acid triggers a protective autophagy by inhibiting the JAK2/STAT3 pathway in cerebral ischemia/reperfusion injury
Rehni et al. Blockade of acid-sensing ion channels attenuates recurrent hypoglycemia-induced potentiation of ischemic brain damage in treated diabetic rats
Nguyen et al. Journal of Health Science and Development
Win et al. JNK mediation of acetaminophen (APAP) hepatotoxicity is determined by Sab (SH3BP5) dependent dysregula-tion of intramitochondrial c-Src kinase: 49

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)